Evommune, Inc. (EVMN) Key Metrics
EVMN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $187.6M
- Enterprise value
- $125.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 18.8
- Price / book
- 1.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
EVMN key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsEVMN returns How much profit the business earns on the capital it uses.
EVMN per-share figures Results divided by the shares outstanding at year-end.
EVMN financial health Debt, liquidity and how easily interest is covered.
EVMN efficiency & capital use Working capital cycle and where the cash goes.
EVMN valuation history
EVMN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EVMN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EVMN price vs earnings per share
EVMN key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $539.7M | — | — |
| Enterprise value | $392.6M | — | — |
| Price / sales | 41.5 | — | — |
| Price / book | 2.6 | — | — |
| EV / sales | 30.2 | — | — |
| Earnings yield | −12.8% | — | — |
| Free cash flow yield | −14.2% | — | — |
| Share price at fiscal year-end | $17.12 | — | — |
| Per share | |||
| Revenue per share | $0.41 | $0.23 | $0.17 |
| Earnings per share | −$2.18 | −$2.22 | −$1.13 |
| Operating cash flow per share | −$2.42 | −$1.93 | −$1.00 |
| Free cash flow per share | −$2.43 | −$1.94 | −$1.00 |
| Cash per share | $4.73 | $2.40 | $2.63 |
| Book value per share | $6.52 | −$4.80 | −$2.58 |
| Tangible book value per share | $6.52 | −$4.80 | −$2.58 |
| Capex per share | $0.01 | $0.00 | $0.00 |
| Debt per share | $0.07 | $6.43 | $5.01 |
| Shares outstanding | 31.5M | 30.1M | 30.1M |
| Change in shares outstanding | +4.8% | 0.0% | — |
| Returns & profitability | |||
| Return on equity (ROE) | −224.6% | — | — |
| Return on invested capital (ROIC) | −361.2% | — | — |
| Return on assets (ROA) | −45.8% | −84.4% | −41.4% |
| Return on tangible assets | −30.6% | −87.8% | −41.4% |
| Free cash flow margin | −589.8% | −832.6% | −601.8% |
| Financial health | |||
| Total debt | $2.1M | $193.3M | $150.6M |
| Cash & short-term investments | $149.2M | $72.0M | $79.1M |
| Net debt | −$147.1M | $121.3M | $71.5M |
| Debt / equity | 0.01 | — | — |
| Debt / assets | 0.01 | 2.54 | 1.83 |
| Current ratio | 8.57 | 2.64 | 11.67 |
| Quick ratio | 8.57 | 2.64 | 11.67 |
| Interest coverage | — | — | -652.6 |
| Working capital | $135.6M | $46.0M | $73.2M |
| Invested capital | $58.4M | −$23.0M | −$6.2M |
| Tangible asset value | $205.6M | −$144.2M | −$77.7M |
| Net current asset value | $134.1M | −$146.3M | −$79.9M |
| Graham net-net per share | $4.12 | −$4.93 | −$2.69 |
| Capital allocation | |||
| Capex / revenue | 1.8% | 1.3% | 2.4% |
| Capex / depreciation | 0.17 | 0.07 | 0.12 |
| Stock-based compensation / revenue | 45.0% | — | — |
| R&D / revenue | 569.6% | 917.8% | 639.9% |
| SG&A / revenue | 154.1% | — | — |
| Efficiency | |||
| Days payables outstanding | 2,104.9 | 1,421.1 | 641.7 |
| Payables turnover | 0.17 | 0.26 | 0.57 |
| Asset turnover | 0.09 | 0.09 | 0.06 |
| Average payables | $8.0M | $5.0M | $1.8M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% |
Computed from EVMN's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EVMN valuation and financial ratios
Evommune earned a return on equity of −224.6% and a return on invested capital of −361.2% in fiscal 2025. It ended the year with $2.1 million of debt and $149.2 million in cash and short-term investments, a net cash position of $147.1 million.
See the EVMN income statement, the EVMN chart for price history, or the EVMN stock overview for the latest quote and news.
EVMN key metrics FAQ
What is Evommune's return on equity?
Evommune's return on equity (ROE) was −224.6% in fiscal 2025: net income of -$68.9 million on average shareholders' equity of $30.7 million.
What is Evommune's ROIC?
Evommune's return on invested capital was −361.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Evommune have?
Evommune had total debt of $2.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Evommune's free cash flow yield?
Evommune generated -$76.7 million of free cash flow in fiscal 2025, a free cash flow yield of −14.2% on its market value at year-end ($539.7 million).
What is Evommune's current ratio?
Evommune's current ratio was 8.57 at the end of fiscal 2025: current assets were 8.57 times current liabilities.